Cost-effectiveness research mainly focused on integrated enzyme inhibitors (39.5%) and protease inhibitors (15.2%), with the effectiveness determined by either QALYs (60.6%), the rate of successful treatment (18.2%), Lys (12.1%), or DALYs (9.1%).